Hua Medicine Ltd. provides drug discovery and development services. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2018-09-14. The firm is also engaged in the commercialization of HuaTangNing products. The Company’s main product pipeline dorzagliatin or HMS5552 is a glucokinase activator or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The firm mainly conducts its business in the domestic market.
Follow-Up Questions
Hua Medicine 的 CEO 是誰？
Dr. Li Chen 是 Hua Medicine 的 Chief Executive Officer，自 2010 加入公司。
HUMDF 股票的價格表現如何？
HUMDF 的當前價格為 $0，在上個交易日 decreased 了 0%。
Hua Medicine 的主要業務主題或行業是什麼？
Hua Medicine 屬於 Pharmaceuticals 行業，該板塊是 Health Care
